Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

Clinical trial NCT07465276 · RECRUITING

Trial details

NCT number: NCT07465276
Sponsor: Dana-Farber Cancer Institute
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Head and Neck Squamous Cell Carcinoma (HNSCC)Squamous Cell Carcinoma of the Head and Neck

Start date: 2026-03-26
Primary completion: 2028-04-30
Enrollment: 32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.